Elicera Q2: Developing CARMA – Data strengthens ELC-301 outlook - Redeye

Redeye returns with an updated view following Elicera’s Q2 report and encouraging data from the phase I/II CARMA study, evaluating ELC-301 in diffuse large B-cell lymphoma (DLBCL). In light of the new data, we raise our likelihood of approval (LoA) assumptions for ELC-301 and make minor positive commercial adjustments, resulting in a higher valuation range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1126123/elicera-q2-developing-carma-data-strengthens-elc-301-outlook?utm_source=finwire&utm_medium=RSS